tradingkey.logo

Bio Rad Laboratories Inc

BIOb

280.451USD

-1.499-0.53%
Market hours ETQuotes delayed by 15 min
7.59BMarket Cap
23.78P/E TTM

Bio Rad Laboratories Inc

280.451

-1.499-0.53%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-16

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
110 / 207
Overall Ranking
271 / 4724
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 4.97M shares, decreasing 0.06% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated2025-09-16

The company's current financial score is 6.44, which is lower than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 585.40M, representing a year-over-year decrease of 4.16%, while its net profit experienced a year-over-year decrease of 83.33%.

Score

Industry at a Glance

Previous score
8.17
Change
0

Financials

8.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

7.10

Operational Efficiency

9.18

Growth Potential

8.86

Shareholder Returns

7.43

Company Valuation

Currency: USD Updated2025-09-16

The company’s current valuation score is 3.60, which is higher than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 26.54, which is -114.76% below the recent high of -3.92 and 159.06% above the recent low of -15.68.

Score

Industry at a Glance

Previous score
2.05
Change
5

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 110/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-16

There is no earnings forecast score for this company; the Healthcare Equipment & Supplies industry's average is 7.66.

Score

Industry at a Glance

Previous score
0.00
Change
0

Support & Resistance

No Data
No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-16

The company’s current price momentum score is 9.06, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 397.07 and the support level at 95.67, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
0.00
Change
0

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(4)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-24.627
Neutral
RSI(14)
42.335
Neutral
STOCH(KDJ)(9,3,3)
46.391
Sell
ATR(14)
106.755
High Vlolatility
CCI(14)
-155.556
Sell
Williams %R
100.000
Oversold
TRIX(12,20)
1.756
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
226.930
Buy
MA10
201.240
Buy
MA20
218.850
Buy
MA50
189.833
Buy
MA100
121.123
Buy
MA200
145.600
Buy

Institutional Confidence

Currency: USD Updated2025-09-16

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 98.11%, representing a quarter-over-quarter increase of 0.00%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Blue Raven Partners, L.P.
4.06M
--
Alice N. Schwartz Revocable Trust
437.51K
-0.08%
Schwartz (Norman D)
374.47K
+0.03%
Schwartz (Alice N)
57.00K
--
Schwartz (Steven D)
38.24K
+0.15%
Allison (Schwartz)
4.00K
+1.45%
CSS, LLC
1.09K
-18.57%
Buckingham Strategic Wealth, LLC
760.00
--
Morgan Stanley Smith Barney LLC
692.00
--
Wells Fargo Advisors
170.00
--
1
2

Risk Assessment

Currency: USD Updated2025-09-16

The company's beta value is 0.81. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.91
Change
0
Beta vs S&P 500 index
0.82
VaR
--
240-Day Maximum Drawdown
+100.00%
240-Day Volatility
--
Return
Best Daily Return
60 days
--
120 days
--
5 years
--
Worst Daily Return
60 days
-100.00%
120 days
-100.00%
5 years
--
Sharpe Ratio
60 days
--
120 days
--
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+100.00%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
--
3 years
-0.07
5 years
-0.10
Skewness
240 days
--
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
--
5 years
--
Standardised True Range
240 days
+35.78%
5 years
+61.81%
Downside Risk-Adjusted Return
120 days
--
240 days
--
Maximum Daily Upside Volatility
60 days
--
Maximum Daily Downside Volatility
60 days
--
Liquidity
Average Turnover Rate
60 days
--
120 days
--
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--

Peer Comparison

Healthcare Equipment & Supplies
Bio Rad Laboratories Inc
Bio Rad Laboratories Inc
BIOb
5.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.98 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
7.94 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
WST
7.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
7.73 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
7.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI